BRPI0821611A8 - Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu - Google Patents

Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu

Info

Publication number
BRPI0821611A8
BRPI0821611A8 BRPI0821611A BRPI0821611A BRPI0821611A8 BR PI0821611 A8 BRPI0821611 A8 BR PI0821611A8 BR PI0821611 A BRPI0821611 A BR PI0821611A BR PI0821611 A BRPI0821611 A BR PI0821611A BR PI0821611 A8 BRPI0821611 A8 BR PI0821611A8
Authority
BR
Brazil
Prior art keywords
opioid receptor
compounds
carboxypropyl
receptor antagonists
related compounds
Prior art date
Application number
BRPI0821611A
Other languages
English (en)
Inventor
G Trapp Sean
Leadbetter Michael
Van Dyke Priscilla
D Long Daniel
R Jacobsen John
Colson Pierre-Jean
Rapta Miroslav
Yu Ying
Original Assignee
Theravance Inc
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc, Theravance Biopharma R&D Ip Llc filed Critical Theravance Inc
Publication of BRPI0821611A2 publication Critical patent/BRPI0821611A2/pt
Publication of BRPI0821611A8 publication Critical patent/BRPI0821611A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE 3-CARBOXIPROPIL-AMINOTETRALINA E COMPOSTOS RELACIONADOS COMO ANTAGONISTAS DO RECEPTOR OPIÓIDE MU. A invenção fornece compostos de 3-carboxipropilaminotetralina de fórmula (I): em que R1, R2, R3, R4, R5 e R6 são definidos na especificação, ou um sal farmaceuticamente aceitável deste, que são antagonistas no receptor opióide mu. A invenção também fornece composições farmacêuticas que compreendem estes compostos, métodos de utilização destes compostos para tratar condições associadas à atividade do receptor opióide mu, e processos e intermediários úteis para a preparação destes compostos.
BRPI0821611A 2007-12-11 2008-12-10 Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu BRPI0821611A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US722007P 2007-12-11 2007-12-11
US4921908P 2008-04-30 2008-04-30
PCT/US2008/086171 WO2009076408A2 (en) 2007-12-11 2008-12-10 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists

Publications (2)

Publication Number Publication Date
BRPI0821611A2 BRPI0821611A2 (pt) 2015-08-25
BRPI0821611A8 true BRPI0821611A8 (pt) 2016-12-13

Family

ID=40521484

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821611A BRPI0821611A8 (pt) 2007-12-11 2008-12-10 Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu

Country Status (18)

Country Link
US (5) US8106232B2 (pt)
EP (1) EP2231585B1 (pt)
JP (1) JP5403762B2 (pt)
KR (1) KR101610165B1 (pt)
CN (1) CN101896455B (pt)
AR (1) AR072336A1 (pt)
AU (1) AU2008335210B2 (pt)
BR (1) BRPI0821611A8 (pt)
CA (1) CA2707981C (pt)
CL (1) CL2008003672A1 (pt)
CO (1) CO6300937A2 (pt)
ES (1) ES2402749T3 (pt)
IL (1) IL205949A (pt)
MY (1) MY149973A (pt)
NZ (1) NZ586048A (pt)
RU (1) RU2482107C2 (pt)
TW (1) TWI412360B (pt)
WO (1) WO2009076408A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP5350217B2 (ja) * 2006-03-29 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールチオヒダントイン化合物
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
EP2231589B1 (en) 2007-12-11 2013-02-13 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists
EP2280933B1 (en) 2008-04-01 2013-07-24 Theravance, Inc. 2 -aminotetralin derivatives as mu opioid receptor antagonists
SG172016A1 (en) * 2008-12-10 2011-07-28 Theravance Inc Crystalline forms of a 3-carboxypropyl-aminotetralin compound
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
AU2134900A (en) * 1998-12-22 2000-07-12 Astra Pharma Inc. Novel oxo-aminotetralin compounds useful in pain management
US6844368B1 (en) 1998-12-22 2005-01-18 Edward Roberts Compounds useful in pain management
US6498196B1 (en) 1998-12-22 2002-12-24 Edward Roberts Compounds useful in pain management
AU3092800A (en) * 1998-12-22 2000-07-12 Astra Pharma Inc. Novel thio-aminotetralin compounds useful in pain management
US6231594B1 (en) * 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
MX2009004965A (es) 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
EP2231589B1 (en) 2007-12-11 2013-02-13 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists
EP2280933B1 (en) 2008-04-01 2013-07-24 Theravance, Inc. 2 -aminotetralin derivatives as mu opioid receptor antagonists
SG172016A1 (en) * 2008-12-10 2011-07-28 Theravance Inc Crystalline forms of a 3-carboxypropyl-aminotetralin compound

Also Published As

Publication number Publication date
RU2482107C2 (ru) 2013-05-20
AU2008335210A1 (en) 2009-06-18
CO6300937A2 (es) 2011-07-21
AU2008335210B2 (en) 2013-10-10
CN101896455B (zh) 2015-04-29
IL205949A0 (en) 2010-11-30
RU2010128542A (ru) 2012-01-27
US8318765B2 (en) 2012-11-27
TW200932211A (en) 2009-08-01
KR20100100939A (ko) 2010-09-15
MY149973A (en) 2013-11-15
US20140329845A1 (en) 2014-11-06
EP2231585A2 (en) 2010-09-29
US20090149535A1 (en) 2009-06-11
US8969370B2 (en) 2015-03-03
WO2009076408A3 (en) 2009-09-03
WO2009076408A2 (en) 2009-06-18
ES2402749T3 (es) 2013-05-08
US8703791B2 (en) 2014-04-22
CL2008003672A1 (es) 2009-05-29
EP2231585B1 (en) 2013-02-13
US8492399B2 (en) 2013-07-23
BRPI0821611A2 (pt) 2015-08-25
AR072336A1 (es) 2010-08-25
JP5403762B2 (ja) 2014-01-29
US20120088787A1 (en) 2012-04-12
US20130035510A1 (en) 2013-02-07
IL205949A (en) 2014-03-31
NZ586048A (en) 2012-06-29
JP2011506463A (ja) 2011-03-03
CN101896455A (zh) 2010-11-24
TWI412360B (zh) 2013-10-21
CA2707981A1 (en) 2009-06-18
KR101610165B1 (ko) 2016-04-08
CA2707981C (en) 2016-05-10
US8106232B2 (en) 2012-01-31
US20140031380A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
BRPI0607015A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
BR112014011850A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
BR112013016595A2 (pt) inibidores de neprilisina
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
BRPI1014877B8 (pt) compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BR112014012217A2 (pt) derivados de 2-fenilaminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
BRPI0807615A8 (pt) Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
BRPI0921097B8 (pt) composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]